Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.
Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, Tohyama O, Semba T, Yamaguchi A, Hoshi SS, Mimura F, Haneda T, Fukuda Y, Kamata JI, Takahashi K, Matsukura M, Wakabayashi T, Asada M, Nomoto KI, Watanabe T, Dezso Z, Yoshimatsu K, Funahashi Y, Tsuruoka A.
Yamamoto Y, et al. Among authors: yoshimatsu k.
Vasc Cell. 2014 Sep 6;6:18. doi: 10.1186/2045-824X-6-18. eCollection 2014.
Vasc Cell. 2014.
PMID: 25197551
Free PMC article.